Zepeda-Orozco Lab
Acute kidney injury is a common disease. It increases susceptibility to further renal insults and can lead to progressive kidney damage. Currently there is no specific treatment to prevent acute kidney injury or progressive kidney disease.
The Zepeda-Orozco Lab studies the implications of tubular epithelial cells mitochondrial metabolism and oxidative stress in acute kidney injury and chronic kidney disease progression. Its research is devoted to the development of novel diagnostic and therapeutic approaches for prevention and targeted treatment of acute kidney injury-induced progressive kidney damage.
Its team utilizes in-vivo and in-vitro tools to disrupt mitochondrial oxidative metabolism and redox balance in tubular epithelial cells. In combination with the use of pre-clinical kidney injury models, the Zepeda-Orozco Lab is interested in discovering the mechanism regulating mitochondrial adaptation to acute kidney injury and chronic kidney disease. In its models, Dr. Zepeda-Orozco’s team evaluates serum and urine kidney injury biomarkers that will facilitate development of targeted novel therapeutic approaches to prevent or ameliorate acute kidney injury and progressive kidney damage. They expect that the mechanistic studies in these models will ultimately lead testing the effects of novel mitochondrially targeted therapeutic approaches to protect individuals from acute kidney injury and progressive kidney damage.
